Analyst Price Targets — PSNL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 26, 2026 2:35 pm | Subbu Nambi | Guggenheim | $13.00 | $10.53 | TheFly | Personalis price target raised to $13 from $12 at Guggenheim |
| December 1, 2025 9:33 pm | Kallum Titchmarsh | Morgan Stanley | $11.00 | $9.68 | TheFly | Personalis assumed with an Equal Weight at Morgan Stanley |
| November 5, 2025 1:50 pm | Thomas Flaten | Lake Street | $11.00 | $8.25 | TheFly | Personalis price target raised to $11 from $9 at Lake Street |
| November 5, 2025 11:16 am | Mike Matson | Needham | $10.00 | $8.73 | StreetInsider | Personalis (PSNL) PT Raised to $10 at Needham |
| August 6, 2025 5:45 pm | Mark Massaro | BTIG | $6.00 | $4.41 | TheFly | Personalis price target lowered to $6 from $8 at BTIG |
| August 19, 2024 9:12 am | Thomas Flaten | Lake Street | $8.00 | $5.91 | TheFly | Personalis price target raised to $8 from $4 at Lake Street |
| August 19, 2024 6:08 am | Swayampakula Ramakanth | H.C. Wainwright | $9.00 | $5.99 | TheFly | Personalis price target raised to $9 from $7.50 at H.C. Wainwright |
| August 16, 2024 2:52 pm | Mark Massaro | BTIG | $7.00 | $5.99 | StreetInsider | Personalis (PSNL) PT Raised to $7 at BTIG |
| August 8, 2024 1:25 pm | Mark Massaro | BTIG | $5.50 | $3.43 | StreetInsider | Personalis (PSNL) PT Raised to $5.50 at BTIG |
| August 8, 2024 6:28 am | Mike Matson | Needham | $5.50 | $2.88 | StreetInsider | Personalis (PSNL) PT Raised to $5.50 at Needham |
Latest News for PSNL
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that an oral podium presentation featuring colorectal cancer data for the company's NeXT Personal ultrasensitive ctDNA assay and three posters will be presented at the American Association for Cancer Research (AACR) Annual Meeting April 17-22, 2026, in San Diego, California. A…
Aberdeen Group plc lifted its holdings in shares of Personalis, Inc. (NASDAQ: PSNL) by 36.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,249,895 shares of the company's stock after acquiring an additional 861,948 shares during the
Shares of Personalis, Inc. (NASDAQ: PSNL - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the seven research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the 25th Annual Needham Virtual Conference on Wednesday, April 15, 2026. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new…
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the promotion of Richard Chen, M.D., M.S., to the position of President. Dr. Chen will continue to serve as CMO of Personalis in addition to his new role. The appointment comes at a critical inflection point as Personalis transitions from a pioneering R&D powerhouse into a market…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PSNL.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.